We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-10.11%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$301M
AUM Growth
+$23.8M
Cap. Flow
+$67.7M
Cap. Flow %
22.49%
Top 10 Hldgs %
83.86%
Holding
26
New
5
Increased
13
Reduced
3
Closed
3

Top Buys

1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.5M
2
ALIM
Alimera Sciences
ALIM
+$13.2M
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$8.26M
4
EOLS icon
Evolus
EOLS
+$6.03M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.67M

Top Sells

1
THRD
Third Harmonic Bio
THRD
+$13.4M
2
URGN icon
UroGen Pharma
URGN
+$4.64M
3
CSTL icon
Castle Biosciences
CSTL
+$1.26M
4
MXCT icon
MaxCyte
MXCT
+$825K
5
SCYX icon
SCYNEXIS
SCYX
+$280K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$48.1M 15.98%
658,794
+39,368
+6% +$3.14M
EOLS icon
2
Evolus
EOLS
$377M
$47.3M 15.72%
5,179,004
+672,807
+15% +$6.03M
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$1.97B
$46.1M 15.3%
2,515,868
+1,394,840
+124% +$29.5M
ADMA icon
4
ADMA Biologics
ADMA
$2.02B
$32.6M 10.83%
9,104,275
+310,954
+4% +$1.2M
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$27.7M 9.21%
802,544
+119,880
+18% +$4.67M
ALIM
6
DELISTED
Alimera Sciences
ALIM
$12.3M 4.1%
+3,983,686
New +$13.2M
MXCT icon
7
MaxCyte
MXCT
$133M
$11.7M 3.9%
3,761,640
-205,276
-5% -$825K
XERS icon
8
Xeris Biopharma Holdings
XERS
$1.52B
$11M 3.66%
5,915,372
+415,144
+8% +$951K
GMDA
9
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.2M 2.73%
7,965,865
+6,465,865
+431% +$8.26M
ATYR
10
aTyr Pharma
ATYR
$50M
$7.31M 2.43%
4,626,624
-600
-0% -$1.11K
SCYX icon
11
SCYNEXIS
SCYX
$42.4M
$6.5M 2.16%
356,575
-11,718
-3% -$280K
XOMA
12
DELISTED
Xoma
XOMA
$6.15M 2.04%
436,602
+87,203
+25% +$1.37M
XFOR icon
13
X4 Pharmaceuticals
XFOR
$360M
$5.75M 1.91%
175,790
+22,281
+15% +$972K
AVIR icon
14
Atea Pharmaceuticals
AVIR
$390M
$5.16M 1.71%
1,720,000
+967,912
+129% +$3.29M
RZLT icon
15
Rezolute
RZLT
$444M
$4.06M 1.35%
3,072,476
– –
TELA icon
16
TELA Bio
TELA
$32.7M
$3.94M 1.31%
491,919
+9,300
+2% +$86.4K
XGN icon
17
Exagen
XGN
$106M
$2.91M 0.97%
1,203,491
+154,139
+15% +$391K
IOBT
18
DELISTED
IO Biotech
IOBT
$2.79M 0.93%
+1,975,308
New +$3.47M
GOSS icon
19
Gossamer Bio
GOSS
$83.2M
$2.78M 0.92%
+3,339,405
New +$3.85M
DCTH icon
20
Delcath Systems
DCTH
$442M
$2.78M 0.92%
686,240
+307,453
+81% +$1.44M
ASRT
21
DELISTED
Assertio
ASRT
$2.44M 0.81%
+63,413
New +$3.7M
VNDA icon
22
Vanda Pharmaceuticals
VNDA
$327M
$2.06M 0.69%
+477,903
New +$2.66M
AYTU icon
23
AYTU BioPharma
AYTU
$23.1M
$1.28M 0.42%
472,369
– –
CSTL icon
24
Castle Biosciences
CSTL
$733M
– –
-91,978
Closed -$1.26M
THRD
25
DELISTED
Third Harmonic Bio
THRD
– –
-2,793,149
Closed -$13.4M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Stonepine Capital Management held 26 positions worth $301M, up 8.6% from $277M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Stonepine Capital Management deployed $67.7M of net new capital in Q3 2023, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Alimera Sciences: 3,983,686 shares worth $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was MaxCyte, an estimated $825K trimmed.

  • Stonepine Capital Management's largest Q3 2023 buy was Alimera Sciences: 3,983,686 shares worth $12.3M.
  • Stonepine Capital Management added most to Amylyx Pharmaceuticals in Q3 2023, an estimated $29.5M increase.
  • Stonepine Capital Management's biggest Q3 2023 reduction was MaxCyte, cutting an estimated $825K.
  • Stonepine Capital Management fully exited Third Harmonic Bio in Q3 2023, selling an estimated $13.4M.
  • Stonepine Capital Management's ten largest holdings make up 84% of its $301M portfolio in Q3 2023.
  • Stonepine Capital Management opened 5 new positions and closed 3 in Q3 2023.
  • Stonepine Capital Management's portfolio value rose 8.6% quarter-over-quarter to $301M.

Based on Stonepine Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.